With the aim to provide evidence for the relative cardiovascular safety of GnRH agonists and antagonists, the PRONOUNCE study prospectively compared major adverse cardiovascular events (MACE) in prostate cancer patients with preexisting atherosclerotic CVD randomized to receive GnRH agonists versus GnRH antagonists. The gene discussed is GNRH1; the disease is prostate cancer.